Featured Research

from universities, journals, and other organizations

Antibody Targeting Of Glioblastoma Shows Promise In Preclinical Tests

Date:
August 2, 2009
Source:
Georgetown University Medical Center
Summary:
Cancer researchers have successfully tested a small, engineered antibody they say shuts down growth of human glioblastoma tumors in cell and animal studies. Glioblastoma is the deadliest of brain cancers; there is no effective treatment.

Cancer researchers at Georgetown University's Lombardi Comprehensive Cancer Center have successfully tested a small, engineered antibody they say shuts down growth of human glioblastoma tumors in cell and animal studies. Glioblastoma is the deadliest of brain cancers; there is no effective treatment.

In the current online issue of the journal Oncogene, the researchers demonstrate how this antibody latches onto a receptor that studs the outside of glioblastoma cells, preventing a growth factor protein from binding to it and activating growth pathways in the tumors.

"We desperately need new treatments for glioblastoma, and these findings have given us hope that a new approach may be possible," says the study's lead investigator, Anton Wellstein, MD, PhD, a professor of oncology and pharmacology at Lombardi.

He adds that ALK receptors and the protein that binds to it, the growth factor pleiotrophin (PTN), are both also over-expressed in other difficult-to-treat cancers, such as melanoma and pancreatic tumors. "We have found that PTN drives metastasis of those cancers, suggesting that antibody treatment may be additionally useful in those cancers," Wellstein says.

Researchers at Lombardi/Georgetown University Medical Center have been working on this line of research since the mid 1980s, and the institution holds a patent on the "target" of the novel antibody– a region on the ALK receptor. The patent also covers potential therapies. Before Wellstein joined Lombardi in 1989, he worked at the National Cancer Institute with other investigators hunting for growth factors that are secreted by cancer cells, and they eventually reported on PTN in 1992. He and his colleagues spent the next years finding PTN's receptor, which is ALK. They have since characterized the relationship between PTN and ALK, reporting in this study that many brain cancers overexpress PTN and ALK very similar to the developing brain. "When the brain is developing, it needs to constantly remodel itself," he says. "Glioblastoma appears to be another example of cancer that develops when embryonic genes are upregulated. As a result, brain tumor cells are extremely motile and can invade other parts of the brain very quickly."

In this latest research, Wellstein and his colleagues searched public databases, at the National Library of Medicine, to see if other studies that collected and analyzed glioblastoma and other brain tumor tissues also recorded expression of PTN and ALK, as well as genes along this pathway. "We found that they are significantly up regulated," he says. They then assessed whether that activity mattered to the outcome of patients with brain tumors. "A lot of pathways that are activated in cancer are passengers, in a sense. They don't drive cancer. But in the case of PTN and ALK, the expression data suggest that these are drivers – patients with increased expression of these genes had significantly poorer outcomes in an analysis of different, independent studies."

Wellstein had also been working on a method to shut off the pathway. Several years ago, GUMC investigators found the "sweet spot" on ALK where PTN binds, which Wellstein says was a major discovery. "You can have hundreds of different areas on a receptor protein where its ligand could theoretically bind. We found just the right one."

They collaborated with ESBAtech in Switzerland who created a small single-chain antibody fragment in yeast that would itself bind to the sweet spot, blocking ALK's interaction with PTN. In the present study, the researchers successfully tested the antibody in human glioblastoma cells, and also showed that in mice implanted with human glioblastoma, the antibody prevented tumors from growing. For example untreated tumors grew to an average size of 350 cubic millimeters after three weeks, but treated tumors did not grow beyond their initial 25 cubic millimeters.

Wellstein says a phase I clinical trial of the therapy is in the discussion stage, but much remains to be worked out. For example, it is uncertain how the antibody should be administered. Because it may not pass through the blood-brain barrier, it could possibly be delivered through a viral vector, or administered following brain surgery.

While antibodies are used to treat a variety of cancers, such as Herceptin for breast cancer, no antibody treatment has yet been approved for brain diseases, although some are being tested, Wellstein says.

"Developing this approach to treating glioblastoma is very exciting," he says.


Story Source:

The above story is based on materials provided by Georgetown University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Georgetown University Medical Center. "Antibody Targeting Of Glioblastoma Shows Promise In Preclinical Tests." ScienceDaily. ScienceDaily, 2 August 2009. <www.sciencedaily.com/releases/2009/07/090731085821.htm>.
Georgetown University Medical Center. (2009, August 2). Antibody Targeting Of Glioblastoma Shows Promise In Preclinical Tests. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2009/07/090731085821.htm
Georgetown University Medical Center. "Antibody Targeting Of Glioblastoma Shows Promise In Preclinical Tests." ScienceDaily. www.sciencedaily.com/releases/2009/07/090731085821.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins